Floatz logo

(R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1,4,5,6,7,8-HEXAHYDRO-4AH-PYRAZOLO(3,4-G)ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE

Fallopian Tube Cancer

Corcept TherapeuticsSmall moleculePhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

124 Active assets in the Fallopian Tube Cancer cohort.

Asset / SponsorPhaseRating
Mirvetuximab Soravtansine
AbbVie
Phase 3BB
Inno-206
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BB
Irinotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Carboplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3BB
Hycamtin
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

(R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1,4,5,6,7,8-HEXAHYDRO-4AH-PYRAZOLO(3,4-G)ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE is also rated in:

Cushing syndromeDormant
BBB
Indicative ·
72 / 100
View asset →
peritoneal neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →